Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018 2019

Details for Mechanism ID: 18441
Country/Region: Nigeria
Year: 2017
Main Partner: Management Sciences for Health
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: USAID
Total Funding: $1,995,787 Additional Pipeline Funding: $746,989

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $0
Care: Orphans and Vulnerable Children (HKID) $161,821
Care: TB/HIV (HVTB) $0
Care: Pediatric Care and Support (PDCS) $136,291
Laboratory Infrastructure (HLAB) $274,875
Strategic Information (HVSI) $37,500
Testing: HIV Testing and Counseling (HVCT) $204,750
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $0
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $1,176,300
Treatment: Pediatric Treatment (PDTX) $4,250
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV By PEP service provision (related to sexual violence services provided) 2018 140
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2018 66
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2018 159
GEND_GBV Number of people receiving post-GBV care 2018 225
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2018 248,751
HTS_TST Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Negative 2018 95,928
HTS_TST Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative 2018 6,481
HTS_TST Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative 2018 2,837
HTS_TST Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative 2018 92,628
HTS_TST Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative 2018 39,754
HTS_TST Service Delivery Point by Agg Age (Facility) TB: <15, Female, Negative 2018 36
HTS_TST Service Delivery Point by Agg Age (Facility) TB: <15, Male, Negative 2018 27
HTS_TST Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative 2018 1,690
HTS_TST Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative 2018 765
HTS_TST Sum of Test Result disaggregates 2018 8,602
HTS_TST_POS By Test Result: Positive 2018 8,602
HTS_TST_POS Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Positive 2018 830
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive 2018 130
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive 2018 98
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive 2018 5,042
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive 2018 2,215
HTS_TST_POS Service Delivery Point by Agg Age (Facility) TB: <15, Female, Positive 2018 2
HTS_TST_POS Service Delivery Point by Agg Age (Facility) TB: <15, Male, Positive 2018 3
HTS_TST_POS Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive 2018 170
HTS_TST_POS Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive 2018 114
OVC_SERV Age/Sex: <1 2018 51
OVC_SERV Age/Sex: 1-9 2018 1,854
OVC_SERV Age/Sex: 10-14 Female 2018 606
OVC_SERV Age/Sex: 10-14 Male 2018 683
OVC_SERV Age/Sex: 15-17 Female 2018 253
OVC_SERV Age/Sex: 15-17 Male 2018 367
OVC_SERV By: Age/sex: 18-24 Female 2018 74
OVC_SERV By: Age/sex: 25+ Female 2018 207
OVC_SERV By: Age/sex: Male 18-24 2018 95
OVC_SERV By: Age/sex: Male 25+ 2018 160
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2018 4,350
OVC_SERV Program Completion: Graduation 2018 4,350
OVC_SERV Sum of Age/Sex disaggregates 2018 1,909
PMTCT_ART Already on ART at beginning of current pregnancy 2018 685
PMTCT_ART New on ART 2018 823
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2018 1,508
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 97,520
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2018 1,511
PMTCT_EID Number of infants with a negative virological test result within 2 months of birth 2018 1,394
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2018 117
PMTCT_STAT By Age (Numerator): Unknown Age 2018 97,520
PMTCT_STAT By Number of known positives: Unknown Age 2018 763
PMTCT_STAT By Number of new negative: Unknown Age 2018 95,930
PMTCT_STAT By Number of new positives: Unknown Age 2018 830
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 97,520
PMTCT_STAT_den By Age (Denominator): Unknown Age 2018 102,655
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 26
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 230
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 25
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 121
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2018 444
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2018 402
TB_ART_den Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 30
TB_ART_den Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 257
TB_ART_den Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 25
TB_ART_den Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 132
TB_PREV By Age/Sex (Numerator): <15, Female 2018 1,388
TB_PREV By Age/Sex (Numerator): <15, Male 2018 614
TB_PREV By Age/Sex (Numerator): 15+, Female 2018 12,467
TB_PREV By Age/Sex (Numerator): 15+, Male 2018 5,361
TB_PREV By Therapy type (Numerator): 6-12 Month IPT 2018 19,830
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2018 19,830
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2018 28,332
TB_PREV_den By Age/Sex (Denominator): <15, Female 2018 1,977
TB_PREV_den By Age/Sex (Denominator): <15, Male 2018 861
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2018 17,841
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2018 7,653
TB_PREV_den By Therapy type (Denominator): 6-12 Month IPT 2018 28,332
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 144
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 1,033
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 45
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 458
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2018 1,680
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2018 1,868
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 125
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 1,148
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 80
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 515
TX_CURR Aggregated Age/Sex: <15 Female 2018 1,136
TX_CURR Aggregated Age/Sex: <15 Male 2018 510
TX_CURR Aggregated Age/Sex: 15+ Female 2018 19,966
TX_CURR Aggregated Age/Sex: 15+ Male 2018 8,526
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2018 30,138
TX_CURR Sum of Aggregated Age/Sex <15 2018 1,646
TX_CURR Sum of Aggregated Age/Sex 15+ 2018 28,492
TX_CURR Sum of Aggregated Age/Sex disaggregates 2018 30,138
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2018 182
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2018 109
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2018 5,205
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2018 2,193
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 7,688
TX_NEW Sum of Aggregated Age/Sex disaggregates 2018 7,689
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2018 28,630
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2018 25,767
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 1,798
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 801
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 16,199
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 6,969
TX_PVLS Numerator: Indication: Routine 2018 25,767
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 2,000
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 885
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 18,003
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 7,742
TX_PVLS_den Denominator: Indication: Routine 2018 28,630
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 1,766
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 816
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 16,126
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 6,936
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2018 25,644
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2018 28,493
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 1,989
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 880
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 17,917
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 7,707
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2018 9,044
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2018 1,811
TX_TB Numerator: By Aggregated Age/Sex: <15, Female 2018 123
TX_TB Numerator: By Aggregated Age/Sex: <15, Male 2018 79
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2018 1,106
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2018 503
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2018 627
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2018 299
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2018 5,664
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2018 2,454
Cross Cutting Budget Categories and Known Amounts Total: $1,968,563
Gender: Gender Based Violence (GBV) $111,267
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Post GBV Care
Collection and Use of Gender-related Strategic Information
Capacity building
Monitoring and Evaluation
Gender: Gender Equality $6,846
Changing harmful gender norms and promoting positive gender norms
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Promoting gender-related policies and laws that increase legal protection
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Increase gender-equitable access to income and productive resources, including education
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Equity in HIV prevention, care, treatment and support
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Food and Nutrition: Commodities $295,285
Human Resources for Health $1,377,994
Economic Strengthening $157,485
Condoms: Policy, Tools, and Services $19,686